Assignee
BIOXCEL THERAPEUTICS INC
US·17 granted patents·26 pending applications·75 citations·filing 2017–2025
Top patents by PatentIndex Score
43 records- 0197US11806429B2Film formulations containing dexmedetomidine and methods of producing themBIOXCEL THERAPEUTICS INC·Filed 2022·Granted Nov 7, 2023·4 cites·15 claims
- 0297US11559484B2Film formulations containing dexmedetomidine and methods of producing themBIOXCEL THERAPEUTICS INC·Filed 2020·Granted Jan 24, 2023·11 cites·29 claims
- 0397US11517524B2Film formulations containing dexmedetomidine and methods of producing themBIOXCEL THERAPEUTICS INC·Filed 2021·Granted Dec 6, 2022·9 cites·24 claims
- 0497US11497711B2Film formulations containing dexmedetomidine and methods of producing themBIOXCEL THERAPEUTICS INC·Filed 2021·Granted Nov 15, 2022·9 cites·27 claims
- 0597US11478422B2Film formulations containing dexmedetomidine and methods of producing themBIOXCEL THERAPEUTICS INC·Filed 2020·Granted Oct 25, 2022·10 cites·8 claims
- 0696US10792246B2Film formulations containing dexmedetomidine and methods of producing themBIOXCEL THERAPEUTICS INC·Filed 2019·Granted Oct 6, 2020·19 cites·26 claims
- 0795US11806334B1Non-sedating dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2023·Granted Nov 7, 2023·4 cites·5 claims
- 0893US11998529B2Non-sedating dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2023·Granted Jun 4, 2024·1 cites·18 claims
- 0993US11890272B2Non-sedating dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2022·Granted Feb 6, 2024·1 cites·25 claims
- 1093US11786508B2Use of sublingual dexmedetomidine for the treatment of agitationBIOXCEL THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·4 cites·6 claims
- 1192US12109196B2Non-sedating dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2024·Granted Oct 8, 2024·1 cites·25 claims
- 1288US12364683B2Non-sedating dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2024·Granted Jul 22, 2025·0 cites·18 claims
- 1388US12138247B2Non-sedating dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2024·Granted Nov 12, 2024·0 cites·6 claims
- 1487US2023390190A1Film formulations containing dexmedetomidine and methods of producing themBIOXCEL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1587US2023381099A1Film formulations containing dexmedetomidine and methods of producing themBIOXCEL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1686US12090140B2Non-sedating dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2023·Granted Sep 17, 2024·0 cites·6 claims
- 1786US11839604B2Use of sublingual dexmedetomidine for the treatment of agitationBIOXCEL THERAPEUTICS INC·Filed 2017·Granted Dec 12, 2023·2 cites·8 claims
- 1886US2025325521A1Use of sublingual dexmedetomidine for the treatment of agitationBIOXCEL THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1985US2024173299A1Non-sedating dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2084US11998528B1Non-sedating dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2023·Granted Jun 4, 2024·0 cites·18 claims
- 2184US2023140624A1Film formulations containing dexmedetomidine and methods of producing themBIOXCEL THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2283US2024252470A1Use of sublingual dexmedetomidine for the treatment of agitationBIOXCEL THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2382US2024245650A1Non-sedating dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2480US2023218580A1Use of sublingual dexmedetomidine for the treatment of agitationBIOXCEL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2577US2025099430A1Prevention or treatment of sleep disorders using dexmedetomidine formulationBIOXCEL THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2676US11931340B2Use of sublingual dexmedetomidine for the treatment of agitationBIOXCEL THERAPEUTICS INC·Filed 2021·Granted Mar 19, 2024·0 cites·14 claims
- 2776US2026000650A1Non-sedating dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2875US2023414572A1Prevention or treatment of sleep disorders using dexmedetomidine formulationBIOXCEL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2975US2025228833A1Methods and compositions for treating agitationBIOXCEL THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3071US2024024288A1Non-sedating dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3169US2025302808A1Dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3264US2024139169A1Methods and compositions for treating agitationBIOXCEL THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3359US2025319069A1Methods for treating depressive statesBIOXCEL THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3459US2022226288A1Dexmedetomidine treatment regimensBIOXCEL THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3556US2024024289A1Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochlorideBIOXCEL THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3651US2021267944A1Methods for treating agitation using dexmedetomidine hydrochlorideBIOXCEL THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3748US2022395222A1Systems and methods for detection and prevention of emergence of agitationBIOXCEL THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3848US2020317784A1Methods and compositions for treating cancer by modifying multiple arms of the immune systemBIOXCEL THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3947US2022202373A1Systems and methods of using machine learning to detect and predict emergence of agitation based on sympathetic nervous system activitiesBIOXCEL THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4046US2022025061A1Combination therapies for treating disease using an innate immunity modifier and an ox40 agonistBIOXCEL THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4139US2022257759A1Treatment of sarcoma using immunomodulationBIOXCEL THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4234US2023338402A1Treatment regimen for cancer using immunomodulationBIOXCEL THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4327US2022089733A1Novel approach for treatment of cancer using immunomodulationBIOXCEL THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →